Get 40% Off
⚠ Earnings Alert! Which stocks are poised to surge?
See the stocks on our ProPicks radar. These strategies gained 19.7% year-to-date.
Unlock full list

GSK reports positive data from trial of endometrial cancer drug

Published 19/03/2019, 18:20
Updated 19/03/2019, 18:20
© Reuters. GlaxoSmithKline's production building is seen in Montrose, Scotland

(Reuters) - GlaxoSmithKline said on Tuesday a study testing its experimental drug dostarlimab in women with recurrent or advanced endometrial cancer showed promising results.

Results from the GARNET study showed the drug elicited clinically meaningful and durable response rates when used to treat certain types of tumours, GSK said.

GSK said it would apply for marketing approval for dostarlimab in endometrial cancer at the end of 2019.

Dostarlimab was developed as part of a collaboration between Tesaro and AnaptysBio Inc.

GSK agreed to buy U.S. cancer specialist Tesaro for $5.1 billion (3.8 billion pounds) in December, giving it a marketed product for ovarian cancer, Zejula, which belongs to a promising class of medicines.

© Reuters. GlaxoSmithKline's production building is seen in Montrose, Scotland

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.